|
|
|
Market Research Report
Pfizer: Pipeline, Products, Performance, Potential
|
|
PDF by E-Mail Approx. 1-2 business days
Hard Copy/CD-ROM Approx. 3-4 business days
If you need expedited delivery, please call us.
|
|
Table of Contents
- EXECUTIVE SUMMARY
- Introduction
- Current F inancial Position
- Company Performance
- Business Segment Performance
- Geographic Segment Performance
- Company Strategy
- R&D Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Production
- Employees
- Product Performance F orecast
- Pipeline Analysis
- Discontinued R&D Projects
- Conclusions / Outlook
- THERAPEUTIC AREA F OCUS
- R&D PIPELINE
- CARDIOVASCULAR / METABOLISM
- Marketed Products
- Champix
- Lipitor
- Norvasc
- Others
- R&D Projects
- Apixaban
- NOX-B11
- PF-734200
- Growth Forecast
- CENTRAL NERVOUS SYSTEM
- Marketed Products
- Aricept
- Geodon/Zeldox
- Lyrica
- Zoloft
- Others
- R&D Projects
- Dimebon
- PF-4360365
- PF-4856880
- PF-4856881
- S,S-reboxetine
- TS-032
- Growth F orecast
- INFECTIOUS AND RESPIRATORY
- Marketed Products
- Eraxis/Ecalta
- Selzentry/Celsentri
- Vfend
- Zyvox/Zyvoxa
- Others
- R&D Projects
- R343
- Sulopenem
- TT-033
- UK-453061
- Zeven
- Growth Forecast
- UROLOGY
- Marketed Products
- Detrusitol/Detrol
- Toviaz
- Viagra/Revatio
- R&D Projects
- Growth Forecast
- ARTHRITIS AND PAIN
- Marketed Products
- R&D Projects
- ADL5747
- ADL5859
- CCR2 Antagonists
- CP-690550
- Tanezumab
- Growth Forecast
- ONCOLOGY
- Marketed Products
- R&D Projects
- Axitinib
- CovX 060
- Figitumumab
- PD-325901
- PD-332991
- PF-3512676
- PF-4949568
- Growth Forecast
- OPHTHALMOLOGY
- Marketed Products
- Xalatan/Xalcom/Xalacom
- Others
- R&D Projects
- Growth Forecast
- ENDOCRINE DISORDERS
- Marketed Products
- Growth Forecast
- WOMEN' S HEALTHCARE
- Marketed Products
- R&D Projects
- Growth F orecast
- OTHER
- Marketed Products
- R&D Projects
- APPENDIX 1 - FINANCIAL PERFORMANCE
- APPENDIX 2 - KEY CORPORATE EVENTS
- APPENDIX 3 - KEY AGREEMENTS
- Adolor Corporation
- Allergan
- Almirall SA
- Astellas Pharma Inc.
- Aurobindo Pharma/Claris Lifesciences Ltd.
- Auxillium Holdings Inc.
- Bausch & Lomb Inc.
- Bayer Schering Pharma
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celldex Therapeutics
- Coley Pharmaceutical Group Inc.
- Cytos Biotechnology AG
- Eisai
- Elusys Therapeutics
- Five Prime Therapeutics Inc.
- Genentech Inc.
- GlaxoSmithKline
- Graceway Pharmaceuticals LLC
- Hydra Biosciences Inc.
- Icagen Inc.
- Immunicon Corporation
- Incyte Corporation
- International Partnership for Microbicides
- Isis Pharmaceuticals Inc.
- Lavipharm Co
- Ligand Pharmaceuticals Inc.
- Kosan Biosciences
- Medarex Inc.
- Medivation Inc.
- Melior Discovery Inc.
- Merck KGaA
- NicOx SA
- NovaMed Pharmaceuticals Inc.
- Novocell
- Noxxon Pharma AG
- Odyssey Thera Inc.
- Onyx Pharmaceuticals Inc.
- OSI Pharmaceuticals Inc/New York University
- Quark Pharmaceuticals Inc.
- Recordati
- Renovis Inc.
- Rigel Pharmaceuticals Inc.
- Sigma-Tau Pharmaceuticals Inc.
- Silence Therapeutics
- Tacere Therapeutics
- Taisho Pharmaceutical
- TransTech Pharma
- UCB
- Others
- APPENDIX 4 - I NFRASTRUCTURE
- Manufacturing Facilities
- R&D F acilities
- APPENDIX 5 - KEY PHARMACEUTICAL
- SUBSIDIARIES/JOINT VENTURES
- Subsidiaries
- Joint-venture Companies
- APPENDIX 6 - PRODUCT INDEX
INDEX OF TABLES
- Principal Operating Results
- Capital Expenditure By Business Area
- Sales By Business Area
- Operating Income By Business Area
- Identifiable Assets By Business Area
- Sales By Destination
- Long-Lived Assets By Geographical Area
- Key Patent Expiry Dates
- Recent Product Approvals
- Sales By Therapeutic Area/Major Products
- Breakdown Of Cardiovascular/Metabolic Product Sales
- Major Cardiovascular/Metabolism Products, 2008
- Breakdown of CNS Sales
- Major CNS Products, 2008
- Breakdown of Infectious Disease/ Respiratory Sales
- Major Infectious & Respiratory Products, 2008
- Breakdown of Urology Sales
- Major Urology Products, 2008
- Breakdown of Arthritis/Pain Sales
- Major Arthritis and Pain Products, 2008
- Breakdown of Oncology Sales
- Major Oncology Products, 2008
- Breakdown of Opthalmology Sales
- Major Ophthalmology Products, 2008
- Breakdown of Endocrine Sales
- Major Endocrine Disorder Products, 2008
- Breakdown of Other Product Sales
- Major Other Products, 2008
- Pfizer' s Major Manufacturing Sites
INDEX OF CHARTS
- Sales, Costs and Operating Income
- R&D Expenditure & Capital Expenditure
- Capital Expenditure By Business Area
- Sales By Business Area
- Operating Income By Business Area
- Sales By Destination
- Employees and Productivity
- Sales of Current Top Ten Products (2003A-2013E)
- Sales By Therapeutic Area
- Top Selling Products, 2008
- Champix Sales (2006A-2013E)
- Lipitor Sales (2003A-2013E)
- Norvasc Sales (2003A-2013E)
- Apixaban Sales (2010E-2014E)
- Aricept Sales (2003A-2013E)
- Geodon/Zeldox Sales (2003A-2013E)
- Lyrica Sales (2004A-2013E)
- Zoloft Sales (2003A-2013E)
- Selzentry/Celsentri Sales (2007A-2013E)
- Vfend Sales (2003A-2013E)
- Zyvox Sales (2003A-2013E)
- Detrol/Detrol LA Sales (2003A-2013E)
- Viagra Sales (2003A-2013E)
- Celebrex Sales (2003A-2013E)
- Sutent Sales (2006A-2013E)
- Sales Forecast (2010E-2015E)
- Xalatan/Xalcom Sales (2003A-2013E)
- Genotropin Sales (2003A-2013E)
- Fablyn Sales (2010E-2015E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
|
Related Report
|
|
Please inform me when related publications are released
|
View Cart
